The Lupin Biotechnology Research Group was established 4 years ago with a vision to provide affordable, high quality biopharmaceuticals with a focus on biosimilars. Lupin currently has close to 100 scientists who are actively engaged in developing 10 biosimilar products, 8 of which are currently the best-selling blockbuster products in the world. Within just 4 years from conception the Lupin biotechnology group is close to getting marketing authorization for 2 of its oncology products for the Indian market. Clinical Trials on 2 more of its pipeline products are scheduled to start in 2012 and 2 more products went into the pre-clinical stage this fiscal. The group has already filed 13 Patents encompassing Lupin's proprietary vectors, process patents and non-infringing formulations. The Company's biotech scientists have also published 20 research articles in international peer reviewed journals.
Lupin today, offers complete development and manufacture capability for recombinant protein therapeutic products from high yielding and proprietary microbial and mammalian cell culture platforms. The Biotech R&D infrastructure created thus far, offers a complete range of product development capabilities ranging from clone development, process optimization, analytical method development, bioassay, formulation, stability studies, non-clinical and clinical studies backed by a sound understanding of regulatory and IP aspects. From concept to commercial stage, the development programs comply with and follow ICH, EMEA and Indian Regulatory guidelines.